Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2020-04-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized phase II trial studies how well docosahexaenoic acid works in preventing recurrence in breast cancer survivors. Docosahexaenoic acid supplement may prevent recurrence in breast cancer survivors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine whether treatment with docosahexaenoic acid (DHA) for 12 weeks at 1000 mg twice daily as compared to placebo reduces normal breast tissue levels of tumor necrosis factor-alpha (TNF-alpha) in overweight and obese patients with a history of stage I-III invasive breast cancer, ductal carcinoma in situ (DCIS), Paget's disease, lobular carcinoma in situ (LCIS), or proliferative benign breast disease.

SECONDARY OBJECTIVES:

I. To investigate the effect of DHA at 1000 mg twice daily on tissue biomarkers

* Change from the baseline in cyclooxygenase-2 (COX-2)/interleukin-1-beta (IL-1beta)/aromatase measured by quantitative real-time polymerase chain reaction (PCR).
* Change from the baseline in crown-like structures of the breast (CLS-B) measured by immunohistochemical techniques for cluster of differentiation (CD)68.
* Change from baseline in CLS-B index determined as follows: (\[number of slides with evidence of at least one CLS-B\]/\[total number of slides examined\]).
* Change from baseline in CLS-B/cm\^2 defined as the number of CLS-B/cm\^2. II. Evaluate age as a predictor of CLS-B and inflammatory biomarkers (TNF-alpha/COX-2/IL-1beta) at baseline and over the time of treatment.

III. Evaluate red blood cell (RBC) fatty acid level as a surrogate of compliance.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive docosahexaenoic acid orally (PO) twice daily (BID) for 12 weeks.

ARM II: Patients receive placebo PO BID for 12 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Benign Breast Neoplasm Ductal Breast Carcinoma In Situ Invasive Breast Carcinoma Lobular Breast Carcinoma In Situ Paget Disease of the Breast Stage IA Breast Cancer Stage IB Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (Docosahexaenoic Acid)

Docosahexaenoic Acid orally twice a day (PO BID) for 12 weeks.

Group Type EXPERIMENTAL

Docosahexaenoic Acid

Intervention Type DRUG

Given PO

Arm II (placebo)

Placebo orally twice a day (PO BID) for 12 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Given PO

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Docosahexaenoic Acid

Given PO

Intervention Type DRUG

Placebo

Given PO

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fatty Acid 22:6 placebo therapy PLCB sham therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must have a history of histologically-confirmed stage I-III invasive breast cancer or ductal carcinoma in situ (DCIS), Paget's disease, lobular carcinoma in situ (LCIS), or proliferative benign breast disease
* No evidence of disease (in situ or invasive cancer that would normally be treated by resection) at trial entry as determined by the investigator
* \>= 6 months from all previous breast cancer treatment (including surgery for invasive cancer, chest wall radiotherapy, chemotherapy, trastuzumab and endocrine therapy)
* Participants must have a body mass index (BMI) \>= 25, defined as (weight in kilograms/\[height in meters\]\^2)
* Participants must have adequate accessible breast tissue as determined by the treating physician, consisting of one breast unaffected by invasive cancer, which has not been radiated; a history of prior pre-invasive breast cancer or benign biopsy of this breast will be permitted
* Daily DHA consumption =\< 200 mg/day in the month prior to screening estimated by an abbreviated DHA food frequency questionnaire
* Mammogram within no more than 6 months prior to the date of informed consent (normal/benign Breast Imaging-Reporting and Data System \[BI-RADS\] 1 or 2) and no further routine breast imaging planned during the course of the study (12 weeks DHA/placebo)
* Eastern Cooperative Oncology Group (ECOG) performance status must be =\< 2 (Karnofsky \>= 60%)
* Absolute neutrophil count \>= 1,500/uL
* Platelets \>= 75,000/uL
* White blood cells \>= 3,000/uL
* Hemoglobin \>= 10 g/dL
* Total bilirubin within 1.5 times the institution's upper limit of normal (ULN)
* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) within 1.5 times the institution's ULN
* Serum creatinine within 1.5 times the institution's ULN
* Pregnant women will be excluded; for women of childbearing potential; negative pregnancy testing within 72 hours prior to or on study visit #1 (day 0) and willingness to use adequate contraception during the study intervention OR post-menopausal defined as any one of the following 1) prior hysterectomy, 2) absence of menstrual period for 1 year in the absence of prior chemotherapy or 3) absence of menstrual period for 2 years in women with a prior history of chemotherapy exposure who were pre-menopausal prior to chemotherapy
* Willingness to comply with all study interventions and follow-up procedures including the ability to swallow the study drug
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

* Any type of active invasive cancer (excluding breast and non-melanoma skin cancer) within the preceding 18 months
* A history of histologically-confirmed bilateral invasive breast cancer
* Bilateral mastectomy
* Prior history or evidence of metastatic breast cancer
* Prior radiation therapy to the contralateral (unaffected) breast
* Prior history of contralateral (unaffected) breast augmentation with breast implant placement
* History of daily use of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) in the week preceding study entry
* History of DHA supplementation \> 200 mg/day in the month preceding study entry
* History of autoimmune disorder or any illness that requires therapy with chronic steroids or immunomodulators
* History of therapeutic doses of anticoagulants including warfarin and low molecular weight heparin (e.g. for prior deep venous thrombosis and pulmonary embolism) in the preceding year
* Participants may not be receiving any other investigational agents during the study
* Women who have received cancer surgery, chemotherapy, biological therapy (e.g., trastuzumab), or radiotherapy for the treatment of any cancer within 6 months of study participation
* Women who are receiving endocrine therapy for breast cancer treatment or chemoprevention including tamoxifen, letrozole, anastrozole, fulvestrant, or exemestane at the time of screening
* Individuals with severe underlying chronic illness, such as uncontrolled diabetes; ongoing or active infection, psychiatric illness or social situations which in the opinion of the investigator would interfere with study participation
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to DHA or corn/soy oil in placebo agent
* Pregnant, breastfeeding, or women of childbearing potential unwilling to use a reliable contraceptive method

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ayca Gucalp

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Powel H. Brown, MD

Role: STUDY_CHAIR

M.D. Anderson Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Site Status

Columbia University/Herbert Irving Cancer Center

New York, New York, United States

Site Status

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Site Status

MD Anderson Cancer Center

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States